论文部分内容阅读
“自杀基因”疗法一般在治疗之初都疗效显著,随着治疗进程的推移,治疗效果就明显减弱.联合一个辅助性的治疗方法以增强“自杀基因”疗法所介入的某些环节的作用或许会提高“自杀基因”疗法的疗效.本实验着重探讨了从提高机体的免疫功能入手,为提高“自杀基因”疗法疗效而进行联合基因治疗的可行性和合理性.结果发现在以“自杀基因”疗法治疗肿瘤的同时转染mGM-CSF或/和mSCF基因后,并未明显提高其疗效.为了探讨是否可以通过提高抗原提呈功能来增强“自杀基因”疗法的疗效,小鼠在荷瘤前1周,先低剂量地转染mGM-CSF或/和mSCF基因重组腺病毒,而后再进行“自杀基因”的疗法的治疗,结果是预力转染mGM-CSF和mSCF基因能提高“自杀基因”疗法的疗效,mM-CSF的作用要强于mSCF,两者还有一定的协同作用.以同样的方法转染mGM-CSF和mSCF基因并给小鼠荷瘤,而不给予“自杀基因”疗法的治疗,各组小鼠的肿瘤均呈进行性生长,组间无差别.可见实验中所用的低剂量mGM-CSF和mSCF重组腺病毒的预转染并不能产生直接的抗肿瘤作用.
“Suicide gene” therapy is generally effective at the beginning of treatment. As the course of treatment progresses, the therapeutic effect is significantly weakened. Combined with an auxiliary treatment method to enhance the role of some of the links involved in the “suicide gene” therapy may It will improve the efficacy of suicide gene therapy. This experiment focuses on the feasibility and rationality of combining gene therapy to improve the immune function of the body and improve the efficacy of “suicide gene therapy.” “Transfection of mGM-CSF or/and mSCF gene at the same time as treatment of tumors did not significantly improve its efficacy. To investigate whether it is possible to enhance the efficacy of ”suicide gene therapy“ by enhancing antigen presentation, mice are In the first week, the recombinant adenovirus of mGM-CSF or/and mSCF gene was transfected with low-dose first, followed by treatment with “suicide gene” therapy. The result was that pre-transfection of mGM-CSF and mSCF gene could improve suicide. The efficacy of gene therapy, mM-CSF is stronger than mSCF, there is a certain degree of synergy between the two. In the same way transfected mGM-CSF and mSCF gene and tumor bearing mice, without giving In the treatment of ”suicide gene therapy", the tumors of all groups showed progressive growth and there was no difference between groups. It can be seen that the pre-transfection of low-dose mGM-CSF and mSCF recombinant adenovirus used in the experiment does not produce direct resistance. Tumor effect.